AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12269263
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (anthracycline-containing regimens)
Trial: 7490154
Drug: 60 mmol
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mmol potassium and 25 mmol (1000 mg) calcium
Trial: 7490154
Drug: 60 mmol
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mmol potassium and 15 mmol (360 mg) magnesium
Trial: 31858615
Drug: Exhaled volatile
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exhaled volatile organic compounds (VOCs) analysis for CRC detection
Trial: 31858615
Drug: Exhaled volatile
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exhaled volatile organic compounds (VOCs) analysis for advanced adenomas (AAs) detection
Trial: 30502019
Drug: Acetaminophen/hydrocodone 325/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/hydrocodone 325/5 mg (AH, opioid group)
Trial: 30502019
Drug: Acetaminophen/ibuprofen 500/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/ibuprofen 500/400 mg (AIBU, nonopioid group)
Trial: 28482350
Drug: Transfer Capacitive
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer Capacitive Resistive Energy (TCARE) therapy
Trial: 23583457
Drug: Multidisciplinary non‐pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary non‐pharmacological treatment (four sessions)
Trial: 11302006
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g isolated soy protein (ISP) daily
Trial: 9005609
Drug: double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double dose of lomir for 2 weeks
Trial: 6723348
Drug: Spiramycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin (500 mg 3-times daily for 3 days)
Trial: 6723348
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg 3-times daily for 5 days)
Trial: 27310418
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Depression Only (CBT)
Trial: 29983749
Drug: Knee unloading
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee unloading shoes (ASICS GEL-Melbourne OA)
Trial: 21029824
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if needed)
Trial: 15811480
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg/d + Simvastatin (SIMVA) 10, 20, 40, or 80 mg/d
Trial: 7497867
Drug: Standard 75-g
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard 75-g oral glucose tolerance test
Trial: 30658845
Drug: 2000mg acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000mg acetaminophen (propacetamol)
Trial: 27142328
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (Boostrix(®)) during pregnancy
Trial: 25517809
Drug: Tuberculin skin
RxNorm normalized name: tuberculin skin test; unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculin skin test (TST) followed by isoniazid preventive therapy (IPT)
Trial: 19846355
Drug: EAM800x10 (moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAM800x10 (moxifloxacin 400 mg b.i.d. for 10 days)
Trial: 19846355
Drug: EAM800x7 (moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAM800x7 (moxifloxacin 400 mg b.i.d. for 7 days)
Trial: 19846355
Drug: EAM800x5 (moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAM800x5 (moxifloxacin 400 mg b.i.d. for 5 days)
Trial: 19846355
Drug: EAM400x10 (moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAM400x10 (moxifloxacin 400 mg o.i.d. for 10 days)
Trial: 19846355
Drug: Second-line rifabutin-based
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-line rifabutin-based therapy after EAM800x10 and EAM800x7
Trial: 12426976
Drug: 1 g/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/125 mg twice daily
Trial: 12426976
Drug: 500 mg/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/125 mg three times a day
Trial: 8520759
Drug: Nebulized morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized morphine 2.5 mg
Trial: 8520759
Drug: Nebulized morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized morphine 5.0 mg
Trial: 1836894
Drug: Paroxetine 30
RxNorm normalized name: PARoxetine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 30 mg (evening)
Trial: 7042363
Drug: ASA 1500
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 1500 + diazepam 6 mg/day
Trial: 9851956
Drug: Intravenous deuterated
RxNorm normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous deuterated verapamil
Trial: 8209272
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (MIP protocol: mitomycin 6 mg/m2 day I, ifosfamide 1.5 g/m2 days 1 to 3, cisplatin 30 mg/m2 days I to 3, mesna 1,200 mg/m2 days 1 to 3) followed by surgery and additional chemotherapy for responders.
Trial: 2606121
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of 0.3 to 0.5 mg ethinyloestradiol (EE) daily
Trial: 2606121
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of 0.1 mg ethinyloestradiol (EE) daily
Trial: 28437161
Drug: Trastuzumab 8
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks)
Trial: 28437161
Drug: Pertuzumab 840
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A
Trial: 23022704
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg in 100 ml of isotonic saline, intravenously
Trial: 23022704
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml of isotonic saline)
Trial: 3166107
Drug: Diethylcarbamazine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (300 mg) taken orally once a week
Trial: 23993259
Drug: Celebrex 200
RxNorm normalized name: Celebrex 200mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celebrex 200 mg daily
Trial: 18271901
Drug: Serum lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum lithium levels of 0.6-0.75 mmol/L
Trial: 18271901
Drug: Serum lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum lithium levels >0.75 mmol/L
Trial: 18271901
Drug: Abrupt reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt reduction of serum lithium levels >0.2 mmol/L
Trial: 18271901
Drug: Serum lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum lithium level of 0.4 mmol/L
Trial: 14624369
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI) plus nevirapine
Trial: 14624369
Drug: 3 nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 nucleoside reverse‐transcriptase inhibitors (NRTIs) plus nevirapine
Trial: 9097716
Drug: Scanning electron
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scanning electron microscopy with energy dispersive x‐ray analyses (microprobe‐SEM/EDXA) and atomic absorption spectroscopy (AAS)
Trial: 27512098
Drug: Tui Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tui Na therapy
Trial: 27512098
Drug: Placebo Tui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tui Na therapy
Trial: 24955104
Drug: Diaoshi Jifa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaoshi Jifa treatment
Trial: 17251982
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg b.i.d. for 6.5 days with rifampin 600 mg once a day
Trial: 17251982
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg b.i.d. for 6.5 days
Trial: 11967516
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg capsule per day for 6 months)
Trial: 9390958
Drug: CHO (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (1 g/kg)
Trial: 23549037
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with cisplatin
Trial: 23549037
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without cisplatin
Trial: 16298751
Drug: Daily fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fruit (blueberries) consumption (250 g) for three weeks
Trial: 16298751
Drug: Acute fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute fruit ingestion (250 g)
Trial: 3109146
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g Mezlocillin administered at the time of narcosis for 20 min followed by 0.5 g Metronidazol for 10 min, given in 8-hour intervals for three days post-surgery.
Trial: 3109146
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (Mezlocillin and Metronidazol) administered 30 min preoperatively and continued for three days postoperatively.
Trial: 3109146
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic antibiotic treatment).
Trial: 30545653
Drug: Closed incisional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed incisional negative pressure wound therapy (ciNPWT)
Trial: 26507336
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (Inofolic® plus): myo-inositol 4000 mg, folic acid 400 mcg, melatonin 3 mg
Trial: 26507336
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (Inofolic®): myo-inositol 4000 mg, folic acid 400 mcg
Trial: 26507336
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: only folic acid 400 mcg
Trial: 14716729
Drug: Active prevention
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 15 mg in 20 mL DENTAL RINSE [Colgate Total Active Prevention Spearmint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active prevention agents or placebo
Trial: 9683207
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (stavudine and nelfinavir)
Trial: 9683207
Drug: Prolonged induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged induction therapy (saquinavir and nelfinavir)
Trial: 9683207
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (stavudine, lamivudine, saquinavir, and nelfinavir)
Trial: 7830804
Drug: Methotrexate 25
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 25 mg i.m. once a week for 12 weeks, followed by tapering oral dose
Trial: 3146726
Drug: High-dose cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporin (16 mg/kg per day)
Trial: 3146726
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin (9 mg/kg per day) with azathioprine (1 mg/kg per day)
Trial: 3146726
Drug: High-dose cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporin followed by conversion to azathioprine
Trial: 29265187
Drug: Drinking apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking apple juice (0 ml, 50 ml, 100 ml, 200 ml, 300 ml, 400 ml)
Trial: 26840338
Drug: Flexible dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dosing intervals (24±3 hours)
Trial: 26840338
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing intervals (24 hours)
Trial: 26840338
Drug: Flexible and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible and Fixed dosing intervals
Trial: 25070545
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (600 mg fixed-dose)
Trial: 23658438
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg daily)
Trial: 23658438
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Atorvastatin + Etidronate)
Trial: 18387406
Drug: Multivitamin/mineral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/mineral formulation
Trial: 16608514
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (25 g soy protein containing 60 mg isoflavones)
Trial: 7499737
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms sulprostone in 250 saline solution infused at a rate of 100 micrograms/h 12 hours before the abortion
Trial: 24200700
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 5 mg with sufentanil 2.5 μg followed by epidural 2% lidocaine 5 mL (Group L)
Trial: 24200700
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 10 mg with sufentanil 2.5 μg followed by epidural saline 5 mL (Group C)
Trial: 11422013
Drug: oral ARTS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral ARTS (150 mg)
Trial: 11422013
Drug: oral DHA
RxNorm normalized name: Atabex DHA Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral DHA (120 mg)
Trial: 8549572
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Trial: 8549572
Drug: Glucose polymer
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymer solution (330 ml with 150 mg sodium 1-[13C] acetate)
Trial: 8549572
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Trial: 2356344
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (15 ml)
Trial: 2356344
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (20 ml)
Trial: 2356344
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (25 ml)
Trial: 2356344
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% (15 ml)
Trial: 2356344
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (15 ml)
Trial: 30172900
Drug: Lettuce seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lettuce seed (1000 mg daily for two weeks)
Trial: 20356440
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection (treatment group)
Trial: 18793398
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy for depression prior to standard weight loss treatment
Trial: 18793398
Drug: Standard weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight loss treatment alone
Trial: 16354802
Drug: Sitamaquine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitamaquine 1.5 mg kg(‐1) day(‐1)
Trial: 16354802
Drug: Sitamaquine 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitamaquine 1.75 mg kg(‐1) day(‐1)
Trial: 16354802
Drug: Sitamaquine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitamaquine 2.0 mg kg(‐1) day(‐1)
Trial: 16354802
Drug: Sitamaquine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitamaquine 2.5 mg kg(‐1) day(‐1)
Trial: 14668277
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lysine/kg/d
Trial: 14668277
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg lysine/kg/d
Trial: 1521727
Drug: Simvastatin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10-20 mg/day) for 12 weeks
Trial: 1521727
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment (baseline vs 12 weeks)
Trial: 1521727
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (baseline vs 12 weeks)
Trial: 30916916
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) and motor imagery (MI)
Trial: 30916916
Drug: Traditional rehabilitation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional rehabilitation (mime-therapy and myofascial-approach)
Trial: 29220110
Drug: Transdermal opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal opioids
Trial: 29220110
Drug: Polypharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacological therapy
Trial: 29220110
Drug: Antidiabetic drugs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic drugs, antibiotics, previous weak opioid therapy
Trial: 29220110
Drug: Anticoagulant, antidiabetic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant, antidiabetic, and central nervous system drugs
Trial: 27327862
Drug: Abciximab followed
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab followed by a 12-hour infusion
Trial: 24710131
Drug: Prednisolone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 7.5 mg/day in addition to disease-modifying antirheumatic drugs (DMARDs)
Trial: 24710131
Drug: DMARD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD therapy alone
Trial: 8852387
Drug: Hydroxyurea 500
RxNorm normalized name: hydroxyurea 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea 500 mg twice daily
Trial: 8852387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyurea 500 mg twice daily and azidothymidine (AZT) 250 mg twice daily
Trial: 8852387
Drug: Azidothymidine (AZT)
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azidothymidine (AZT) 250 mg twice daily
Trial: 1352931
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Trial: 1352931
Drug: Pancuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Trial: 6371226
Drug: subject-alone relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subject-alone relaxation therapy
Trial: 6371226
Drug: couples-relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: couples-relaxation therapy
Trial: 6371226
Drug: couples-cognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: couples-cognitive therapy
Trial: 27592690
Drug: Intermittent adductor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent adductor canal block (ACB) with 15 ml of 0.5% ropivacaine every 6 hours